ViroPharma, Aventis Picovir deal

VPHM and AVE will co-develop and co-promote in the U.S. VPHM's Picovir pleconaril oral picornavirus inhibitor for viral respiratory infection (the common cold). VPHM will receive a $25 million upfront...